Related Experiment Video
Updated: Jun 12, 2025
08:35
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
6.2K
Experimental Models to Investigate PNPLA3 in Liver Steatosis
Alireza Ramandi1, Anna-Mae Diehl2, Arun J Sanyal3
1Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA.
Summary
The PNPLA3-148M variant increases risk for fatty liver disease. This review examines preclinical models to understand how this genetic factor drives liver disease progression, highlighting species-specific challenges.
Area of Science:
- Genetics
- Hepatology
- Molecular Biology
Background:
- Patatin-like phospholipase domain-containing 3 (PNPLA3) is the first gene linked to hepatic fat accumulation via genome-wide association studies.
- A specific missense variant, PNPLA3-148M, elevates risk for the entire spectrum of steatotic liver disease (SLD), including cirrhosis and liver cancer.
Purpose of the Study:
- To review preclinical models investigating the role of PNPLA3 in SLD.
- To focus on models relevant to metabolic dysfunction-associated steatotic liver disease (MASLD).
- To assess the strengths, limitations, and species-specific challenges of these models.
Main Methods:
- Evaluation of in vitro and in vivo preclinical models.
- Analysis of studies focusing on PNPLA3's pathogenic role in SLD.
- Comparison of human and murine PNPLA3 expression and function.
Main Results:
- Preclinical models are crucial for understanding PNPLA3's role in SLD pathogenesis.
- Significant challenges exist due to species differences in PNPLA3 function.
- Current models offer insights but require careful interpretation for human relevance.
Conclusions:
- Understanding PNPLA3-148M's mechanism requires robust preclinical models.
- Addressing species-specific differences is key to advancing SLD research.
- Further refinement of models is needed to fully elucidate PNPLA3's impact on liver disease progression.
